Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Interventional 18 Observational 1 Expanded_access 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 3 Immunologic Deficiency Syndromes 2 Thalassemia 1 Neoplasms 1 Myelodysplastic Syndromes 1 Muscle Neoplasms 1 Metabolic Diseases 1 Melanoma 1 Lymphoma 1 Hemoglobinopathies 1 Hematologic Neoplasms 1 Fanconi Anemia 1 Chronic Pain 1 Breast Neoplasms 1 Anemia, Sickle Cell 1 Anemia, Aplastic 1

Interventions

Blood Specimen Collection 14 Nivolumab 13 Ipilimumab 12 pembrolizumab 11 trametinib 9 Surveys and Questionnaires 9 Gene Expression Profiling 9 dabrafenib 8 Biopsy 6 Specimen Handling 5 Immunotherapy 5 Immunohistochemistry 5 Amplified Fragment Length Polymorphism Analysis 4 encorafenib 3 binimetinib 3 atezolizumab 3 Restraint, Physical 3 Quality of Life 3 Polymerase Chain Reaction 3 Introns 3 Flow Cytometry 3 Drug Therapy 3 Data Collection 3 tremelimumab 2 pimonidazole 2 cobimetinib 2 aldesleukin 2 Watchful Waiting 2 Vemurafenib 2 Therapeutics 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Melanoma × Melphalan × Clear all

NCT01920516 2019-02-27

ILI

International Group of Endovascular Oncology

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡